Prenetics Global Limited - Class A Ordinary Share (PRE) earnings
PRE earnings moved a median of -1.61% by the close. Quarterly and annual PRE reports and results, each read against the price at its own news timestamp. Back to the PRE overview →
18 measured PRE earnings events.
Where these PRE earnings landedvs 18 measured PRE earnings reactions
| Middle 50% of PRE earnings reactions | -4.46% to +1.93% |
|---|---|
| Median reaction (to close) | -1.61% |
| Measured reactions | 18 |
Point-in-time · zero look-ahead
Half of the 18 PRE earnings events with a measured close landed between -4.46% and +1.93%; 44% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Prenetics’ IM8 CEO and CFO Purchase $1.0 Million of Shares in the Open Market Following Second Quarter Results | Press release | -1.21% | +7.64% | |
| Prenetics’ IM8 Reports Q2 2026 Revenue Growth of 288% YoY; Raises FY 2026 IM8 Revenue Guidance to $220–230 Million; July Was the First Month of Positive Consolidated Adjusted Free Cash Flow and Expected to Remain Positive for Q3 and Beyond | Press release | -1.80% | -1.02% | |
| Prenetics to Report Q2 2026 Financial Results on August 18, 2026, Live-Stream Earnings Event on Stocktwits, and Announces Upcoming Conference Participation | Press release | +2.04% | +2.24% | |
| Prenetics Announces Record Q1 2026 Results with IM8 Revenue Reaching a Record ~$16.7 Million in May, Implying ~$200 Million in Annualized Recurring Revenue | Press release | -1.19% | -4.66% | |
| Prenetics Announces Preliminary Record Q1 2026 Results with IM8 Revenue Growing Nearly 6x YoY; Company Raises Full-Year 2026 IM8 Revenue Guidance to $190M–$210M | Press release | +4.67% | +3.35% | |
| Prenetics to Report Q1 2026 Financial Results on May 14, 2026 and Host Earnings Conference Call | Press release | +0.00% | +1.00% | |
| Prenetics Executives Execute Second Consecutive Round of Post-Earnings Open Market Share Purchases of $1.3 Million— Cumulative Personal Investment Across Both Rounds Reaches $2.7 Million | Press release | +0.13% | -3.47% | |
| Prenetics to Report Q4 and Full Year 2025 Financial Results on Feb 18, 2026 and Host Earnings Conference Call | Press release | -5.82% | -6.39% | |
| Prenetics Reports Record Third Quarter 2025 Results; IM8 on Track for $120M ARR[1] by December 2025, Fastest Supplement Brand Growth in Industry History | Press release | +0.04% | +5.24% | |
| Prenetics Reports Record Third Quarter 2025 Results; IM8 on Track for $120M ARR¹ by December 2025, Fastest Supplement Brand Growth in Industry History | Press release | -0.23% | -9.10% | |
| Prenetics Announces Third Quarter 2025 Financial Results Release Date and Inaugural Earnings Conference Call | Press release | +2.04% | -3.85% | |
| Prenetics Announces Second Quarter 2025 Financial Results with IM8 on Track to Achieve $100M Annual Recurring Revenue by Year's End | Press release | -0.40% | +0.25% | |
| Prenetics Announces Second Quarter 2025 Financial Results with IM8 on Track to Achieve $100M Annual Recurring Revenue by Year’s End | Press release | +0.20% | +0.85% | |
| Prenetics Announces First Quarter 2025 Financial Results, Raises FY2025 Outlook, & Crypto Strategy Announcement Soon | Press release | +1.29% | -5.98% | |
| Prenetics Announces Third Quarter 2024 Financial Results | Press release | — | -2.21% | |
| Prenetics Announces Second Quarter 2024 Financial Results | Press release | -2.03% | -6.69% | |
| Prenetics Announces First Quarter 2024 Financial Results | Press release | +0.00% | -2.46% | |
| Prenetics Announces Third Quarter 2023 Financial Results | Press release | +1.10% | +3.30% |
Keep exploring
More PRE: analyst actions → · SEC filings → · PRE overview →